COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
COMPASS Pathways plcNASDAQ: CMPS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow shrinks to $0
Q1 FY2026 depreciation & amortization was $0, compared with $37K a year earlier. Trailing-twelve-month depreciation & amortization was $179K. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $44.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 216K USD
- Year-over-year change
- -7.3%
- 4-year CAGR
- +5.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 216K | -7.3% |
| FY2024 | 2024-12-31 | 233K | -3.7% |
| FY2023 | 2023-12-31 | 242K | -26.7% |
| FY2022 | 2022-12-31 | 330K | +88.6% |
| FY2021 | 2021-12-31 | 175K | — |
Depreciation & Amortization vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 depreciation & amortization of $179K is the 8th largest of the 11 companies compared; the peer median is $462K.
- Its year-over-year change of -14.4% is the 6th highest of 9, against a peer median of -3.0%.
- Over three fiscal years its annual growth of -13.2% compares with a peer median of +79.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $25.34M | +6.1% | +2.7% | 2.6% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $12.02M | -12.0% | +79.7% | 1.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $350K | +12.5% | +92.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $179K | -14.4% | -13.2% | — | |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
| LTM Jun 2026 | $2.72K | — | +761.4% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | -100.0% | — | — |
| Peer median (excluding CMPS) | $462K | -3.0% | +79.7% | 3.8% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| Deferred Income Tax | 22K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.64M | 13.12M | 17.28M | 19.52M | 13.59M |
| Change in Working Capital | (6.64M) | (30.67M) | 3.48M | 11.72M | (14.28M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (163K) | 2.5M | 864K | 6.59M | 2.03M |
| Other Working Capital | (6.47M) | (33.16M) | 2.62M | 5.13M | (16.32M) |
| Other Non-Cash Items | 1.8M | 3.27M | 86K | 4.46M | 131.1M |
| Operating Cash Flow | (67.75M) | (105.45M) | (97.38M) | (119.19M) | (157.24M) |
| Capital Expenditures | (334K) | (596K) | (66K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2K | 0 | 0 |
| Investing Cash Flow | (334K) | (596K) | (64K) | 0 | 0 |
| Debt Repayment | 0 | 0 | 29.59M | 0 | 0 |
| Common Stock Issued | 154.79M | 440K | 144.94M | 26.22M | 141.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 600K | (690K) | 37.61M | (328.83K) |
| Financing Cash Flow | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Effect of Forex Changes | (5.58M) | (24.96M) | 867K | 194K | 1.05M |
| Net Change in Cash | 82.99M | (129.97M) | 77.26M | (55.17M) | (15.48M) |
| Free Cash Flow | (68.08M) | (106.05M) | (97.44M) | (119.19M) | (157.24M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.